Scholarly article on topic 'Simultaneous Estimation of Paracetamol, Ambroxol Hydrochloride, Levocetirizine Dihydrochloride, and Phenylephrine Hydrochloride in Combined Tablet Formulation by First-Order Derivative Spectrophotometry'

Simultaneous Estimation of Paracetamol, Ambroxol Hydrochloride, Levocetirizine Dihydrochloride, and Phenylephrine Hydrochloride in Combined Tablet Formulation by First-Order Derivative Spectrophotometry Academic research paper on "Chemical sciences"

CC BY
0
0
Share paper
Academic journal
ISRN Spectroscopy
OECD Field of science
Keywords
{""}

Academic research paper on topic "Simultaneous Estimation of Paracetamol, Ambroxol Hydrochloride, Levocetirizine Dihydrochloride, and Phenylephrine Hydrochloride in Combined Tablet Formulation by First-Order Derivative Spectrophotometry"

Hindawi Publishing Corporation ISRN Spectroscopy

Volume 2014, Article ID 248960, 8 pages http://dx.doi.org/10.1155/2014/248960

Research Article

Simultaneous Estimation of Paracetamol, Ambroxol Hydrochloride, Levocetirizine Dihydrochloride, and Phenylephrine Hydrochloride in Combined Tablet Formulation by First-Order Derivative Spectrophotometry

K. Anandakumar and P. Veerasundari

Department of Pharmaceutical Analysis, Adhiparasakthi College of Pharmacy, Melmaruvathur, Tamil Nadu 603 319, India Correspondence should be addressed to K. Anandakumar; anandkarunakaran@gmail.com Received 29 November 2013; Accepted 22 January 2014; Published 30 March 2014 Academic Editors: D.-A. Guo, P.-C. Liao, and N. P. Lopes

Copyright © 2014 K. Anandakumar and P. Veerasundari. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride are used in combination for the treatment of chronic sinusitis, rhinitis, fever, nasal discharge, sore throat, and wheezing. The present work deals with method development for simultaneous estimation of paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride in tablet formulation by first-order derivative spectrosphotometry. For determination of sampling wavelength, 10 ^g/mL of each of paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride was scanned in 200-400 nm ranges and sampling wavelengths were found to be 305.5 nm for paracetamol, 321 nm for ambroxol hydrochloride, 244 nm for levocetirizine dihydrochloride, and 280 nm for phenylephrine hydrochloride in firstorder derivative spectrophotometry. In this method, linearity was observed in the ranges of 20-140 ^g/mL for paracetamol and 10-70 ^g/mL for ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride. The % recovery was within the range between 98 and 102%, and % relative standard deviation for precision and accuracy of the method was found to be less than 2%. The method is validated as per International Conference on Harmonization Guidelines. The method can be successfully applied for the simultaneous analysis of these drugs in pharmaceutical dosage forms.

1. Introduction

Paracetamol (PARA), chemically known as N-(4-hydroxy-phenyl)ethanamide (Figure 1(a)), inhibits the cyclooxygenase (COX) used as an analgesic, antipyretic, and nonnarcotic agent. Ambroxol hydrochloride (AMB), chemically known as trans-S-4-(2-Amino-3, 5-dibrombenzylamino)-cyclohexanol (Figure 1(b)), is an active N-desmethyl metabolite of the mucolytic bromhexine used as an oral mucolytic expectorant. Levocetirizine dihydrochloride (LEVO), chemically known as [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazi-nyl]ethoxy]-acetic acid dihydrochloride (Figure 1(c)), is L-enantiomer of cetirizine racemate. It works by blocking H histamine receptors; it is used for allergic rhinitis and conjunctivitis, hay fever, and pollinosis; it controls

sneezing, runny but not blocked nose, and red, watering, and itchy eyes. Phenylephrine hydrochloride (PHEN), chemically known as (R)-3-hydroxy-alpha [(methylami-no)methyl]benzenemethanol hydrochloride (Figure 1(d)), is a direct acting sympathomimetic agent. It is a selective adrenoceptor agonist and has negligible p action and is used as a nasal decongestant and for producing mydriasis when cycloplegia is not required. PARA, AMB, and PHEN are official in IP [1] and BP [2]. But LEVO is not official in any of the Pharmacopoeia.

Literature survey revealed that there are several methods that have been reported for the estimation of these drugs in combination with other drugs by using UV spectrophotometry [3-12], RP-HPLC [13-36], HPTLC [36-39], and LC-MS [40, 41]. PARA, AMB, LEVO, and PHEN in combination

(c) (d)

Figure 1: Chemical structure of (a) PARA, (b) AMB, (c) LEVO, and (d) PHEN.

are not official in any pharmacopoeia. As per literature, no analytical method could be traced for the analysis of PARA, AMB, LEVO, and PHEN in combined tablet dosage form. Therefore, simple, rapid, and reliable method for simultaneous estimation of these drugs in combination seemed to be necessary.

Spectrophotometric methods of analysis are more economic and simpler, compared to methods such as chro-matography and electrophoresis. Under computer-controlled instrumentation, derivative spectrophotometry is playing a very important role in the multicomponent analysis of mixtures by UV molecular absorption spectrophotometry. Quaternary mixture can be easily resolved by means of a spectrophotometric method, which is based on the simultaneous use of "zero crossing" method. The aim of this work was to investigate the utility of derivative spectrophotometry and to develop reliable spectrophotometric procedure for the simultaneous determination of PARA, AMB, LEVO, and PHEN in combined tablet dosage form without any prior separation of individual drugs. The presently developed method was validated as per International Conference on Harmonization guidelines (ICH) [42, 43].

2. Materials and Methods

2.1. Apparatus and Instrument. A double beam UV-Visible spectrophotometer (Shimadzu, model pharm spec 1700) having two matched quartz cells with 1cm light path and electronic analytical balance (Shimadzu AUX-220) and ultra-sonication (Soltec 2200) were used. Volumetric flasks and pipettes of borosilicate glasses were used in the study.

2.2. Chemicals and Reagents. Pure drug samples of PARA and LEVO were obtained as gift sample from Medopharm Pvt. Ltd., Chennai, Tamil Nadu, India; AMB was gifted by Madras Pharmaceuticals Pvt. Ltd., Chennai, Tamil Nadu,

India; PHEN was gifted by APEX Pharmaceuticals, Chennai, Tamil Nadu, India. Methanol (HPLC grade) was purchased from Qualigens Pvt. Limited, Mumbai, India. Distilled water was obtained from the Double Distillation Unit in our laboratory.

2.3. Marketed Formulation. The marketed formulation studied was 1-AL total tablets manufactured by FDC Limited., Aurangabad, India. Each tablet contains 500 mg of PARA, 60 mg of AMB, 2.5 mg of LEVO, and 5 mg of PHEN.

2.4. Selection of Common Solvent. Methanol was selected as a common solvent to prepare the stock solution and further dilutions were made with distilled water for developing spectral characteristics of these drugs. The selection was made after assessing the solubility of these drugs in different solvents.

2.5. Preparation of Standard Solutions. 50 mg of PARA and 25 mg of AMB, LEVO, and PHEN were weighed accurately, transferred into 25 mL volumetric flask individually, and dissolved with methanol and the volume was made up to 25 mL with methanol. The stock solution contains 2mg/mL of PARA and 1mg/mL of AMB, LEVO, and PHEN.

2.6. Spectrophotometric Conditions

(i) Mode: spectrum

(ii) Scan speed: medium

(iii) Bandwidth: 1 nm

(iv) Wavelength range: 400-200 nm

(v) Absorbance scale: 0.00 A-2.15 A

(vi) Initial baseline correction: distilled water.

2.15A -

0.00 A

(50/div) Wavelength (nm)

Figure 2: Overlain UV spectra of PARA, AMB, LEVO, and PHEN (10 ^g/mL concentration of each drug solution).

-0.19 A

(20/div) Wavelength (nm)

Figure 3: Overlain first-order derivative UV spectra of PARA, AMB, LEVO, and PHEN (10 ^g/mL concentration of each drug solution).

3. First-Order Derivative Spectrophotometric Method

The standard stock solution of PARA, AMB, LEVO, and PHEN was appropriately diluted with distilled water to get the concentration 10 ^g/mL of all the four drugs. Spectra of these diluted solutions were scanned in the spectrum mode between 200 nm and 400 nm using distilled water as a blank. The zero-order spectra of PAR, AMB, LEVO, and PHEN were transformed to corresponding first derivative spectra in the range of 200-400 nm. The overlay spectra (zero- and first-order) of PARA, AMB, LEVO, and PHEN are shown in Figures 2 and 3.

3.1. Selection of Wavelengths. A signal at 305.5 nm of firstorder derivative spectrum was selected for the quantification of PARA where no interference due to AMB, LEVO, and PHEN was observed. Similarly, 321 nm was selected for quantification of AMB where PARA, LEVO, and PHEN did not interfere with the estimation of AMB. At 244 nm, LEVO and PARA showed marked absorbance where as AMB and PHEN have zero crossing point. The absorbance of PARA was interfered in the analysis ofLEVO. Hence, the absorbance ofPARA was corrected for interference from the total absorbance value. With the help of corrected absorbance, the amount of LEVO was calculated at 244 nm. A signal at 280 nm PHEN, PARA, and LEVO showed marked absorbance and AMB has zero crossing point. The absorbance of PARA and LEVO was interfered in the analysis of PHEN. Hence, the absorbance of PARA and LEVO was corrected for interference from the total absorbance value. With the help of the corrected absorbance, the amount of PARA was calculated at 280 nm.

3.2. Calibration Curves for PARA, AMB, LEVO, and PHEN. The standard solutions ofPARA (2 mg/mL), AMB (1 mg/mL), LEVO (1 mg/mL), and PHEN (1 mg/mL) were used to prepare the working standard solution of PARA (20-140 ^g/mL), AMB (10-70 ^g/mL), LEVO (10-70 ^g/mL), and PHEN (1070 wg/mL), respectively. For, these aliquots of 1-7 mL of

standard stock solutions of PARA, AMB, LEVO, and PHEN were transferred separately to a series of 100 mL volumetric flasks and diluted up to the mark with distilled water. The absorbance was measured at 305.5 nm for PARA, 321 nm for AMB, 244 nm for LEVO, and 280 nm for PHEN, respectively. The values of first derivative dA/dA were plotted against corresponding concentrations to construct the calibration curves. The calibration curves are shown in Figure 4.

3.3. Analysis of Tablet Formulation. Marketed tablet formulation containing PARA (500 mg), AMB (60 mg), LEVO (2.5 mg), and PHEN (5 mg) was analyzed using this method. From the triturate of 10 tablets, the amount of tablet powder equivalent to 50 mg of PARA was accurately weighed and transferred into a series of 25 mL volumetric flasks. To that 4 mg/mL solution of AMB, 9.75 mg/mL solution ofLEVO and 9.5 mg/mL solution of PHEN were added and dissolved with methanol and the solution was sonicated for 15 minutes. Then the final volume was made up to 25 mL with methanol. The solution was filtered through Whatmann filter paper Number 41. 3 mL of the stock solution was further diluted to 100 mL with distilled water to get the theoretical concentrations of 60 ^g/mL, 12 ^g/mL, 12 ^g/mL, and 12 ^g/mL of PARA, AMB, LEVO, and PHEN, respectively. The absorbance values were measured at 305.5 nm, 321 nm, 244 nm, and 280 nm for PARA, AMB, LEVO, and PHEN, respectively. The concentration of each analyte was determined with the equations generated from calibration curve of respective drugs. The procedure was repeated for six times.

4. Results and Discussion

4.1. Selectivity. The UV spectra of standard mixture (PARA—60 ^g/mL, AMB—12 ^g/mL, LEVO—12 ^g/mL, and PHEN—12 ^g/mL) and sample solutions (tablet) were recorded between 200 and 400 nm and their dA/dA value was measured. The selectivity of the method was assessed by comparing spectra obtained from formulation

e c 0.014

n a 0.012

rb 0.01 ■

0.008 ■

3 0.006

-0.002

Calibration curve

0.09 0.08 0.07 g 0.06 Si 0.05 S 0.04 S 0.03 0.02 0.01 0

0.02 0.018 0.016 ce 0.014 g 0.012 orb 0.01 obs0.008 bA0.006 0.004 0.002 0

Calibration curve

20 40 60 80 100 120 Concentration (^g/mL)

Calibration curve

140 160

20 30 40 50 60 Concentration (^g/mL)

Calibration curve

20 30 40 50 60 Concentration (^g/mL)

20 30 40 50 60 Concentration (^g/mL)

Figure 4: Calibration curve for (a) PARA, (b) AMB, (c) LEVO, and (d) PHEN.

solution with that obtained from standard drug solution. The UV absorption spectra obtained from standard and sample solutions were found to be identical, confirming the selectivity of the method.

4.2. Linearity. Linear correlation was obtained between dA/dA values versus concentrations of 20-140 ^g/mL for PARA, 10-70 ^g/mL for AMB, LEVO, and PHEN, respectively. Regression parameters are mentioned in Table 1.

4.3. Accuracy. Accuracy of the method was confirmed by recovery studies. Recovery studies were performed by standard addition method at three levels, namely, 80%, 100%, and 120%. Known amounts of pure PARA, AMB, LEVO, and PHEN were added to preanalyzed sample of marketed formulation, and they were subjected to analysis by the proposed method. The recovery was verified by estimation of drug in triplicate preparations at each specified concentration level and calculated %RSD. The recoveries were in the range of 99.77%-99.96%, 99.78%-101.07%, 99.80%-100.95%, and 100.27%-100.31% for PARA, AMB, LEVO, and PHEN, respectively. The low percentage RSD values indicated that there is no interference due to the excipients used in formulation. Hence the accuracy of the method was confirmed. The results of the recovery analysis are shown in Table 2.

4.4. Precision

4.4.1. Repeatability. The precision of the instrument was checked by repeated scanning and measurement of the absorbance of solutions (n = 6) of PARA (10 ^g/mL),

AMB (10 ^g/mL), LEVO (10 pg/mL), and PHEN (10 ^g/mL) without changing the parameters of the proposed method. The %RSD values for PARA, AMB, LEVO, and PHEN were found to be 0.6874, 1.8892, 0.6264, and 1.1750, respectively (Table 3). Low relative standard deviation (<2) indicates that the proposed method is repeatable.

4.4.2. Intermediate Precision. Precision of both methods was determined in terms of intraday and interday variations (%RSD). Intraday precision (%RSD) was assessed by analyzing standard drug solutions within the calibration range, three times on the same day. Interday precision (%RSD) was assessed by analyzing drug solutions within the calibration range on three different days. The intraday and interday precisions were determined, results of which are given in Table 4.

4.5. LOD and LOQ. LOD and LOQ of the drug were calculated as per ICH guideline. LOD values for PARA, AMB, LEVO, and PHEN were found to be 0.0352 ^g/mL, 0.0373 ^g/mL, 0.0645 ^g/mL, and 0.0557 ^g/mL, respectively. LOQ values for PARA, AMB, LEVO, and PHEN were found to be 0.1070 ^g/mL, 0.1132 ^g/mL, 0.1954 ^g/mL and 0.1687 ^g/mL, respectively (Table 1). These data show that the proposed method is sensitive for the determination of PARA, AMB, LEVO, and PHEN.

4.6. Analysis of PARA, AMB, LEVO, and PHEN in Marketed Formulation. Content of PARA, AMB, LEVO, and PHEN found in the marketed formulation from the proposed

Table 1: Regression analysis data and summary of validation parameters for the proposed method.

Parameters First derivative spectrophotometric method

PARA ' AMB' LEVO' PHEN'

Wavelength 305.5 nm 321 nm 244 nm 280 nm

Linearity range (^g/mL) 20-140 10-70 10-70 10-70

Slope (m) 0.00012 0.00026 0.00119 0.00051

Intercept (c) -0.0002 -0.000064 0.000085 0.00031

Correlation coefficient (r2) 0.9992 0.9990 0.9990 0.9995

LOD (^g/mL) 0.0352 0.0373 0.0645 0.0557

LOQ (^g/mL) 0.1070 0.1132 0.1954 0.1687

% Recovery 99.77-99.96 99.28-101.07 99.80-100.95 100.27-100.31

Precision ( RSD) %

Repeatability (n = 6) 0.1661 1.9231 1.6141 1.1750

Interday (n = 3) 0.0726 1.6244 0.0750 0.0763

Intraday (n = 3) 0.4977 0.9453 0.0752 0.0765

'Mean of six observations.

Table 2: Recovery data for the proposed method.

Drug Amount present Amount added Amount estimated Amount recovered Percentage recovered % RSD

(^g/mL)' (^g/mL)' (^g/mL)' (^g/mL)' (n = 6)'

59.6533 47.3221 107.8898 48.2365 101.93 0.2757

PARA 59.6533 60.0016 119.3033 59.6500 99.41 0.2891

59.6533 71.8727 131.4650 71.8117 99.92 0.1703

12.1440 9.6417 21.6966 9.5526 99.08 0.4154

AMB 12.1440 12.0892 24.2021 12.0581 99.74 0.3285

12.1440 14.3880 26.3979 14.2539 99.07 0.7261

12.1176 9.5284 21.6460 9.5284 100.00 0.3518

LEVO 12.1176 12.0916 23.9843 11.8667 98.14 0.3848

12.1176 14.3880 26.3683 14.2507 99.05 0.4868

11.9592 9.5524 21.6182 9.6590 101.11 0.9930

PHEN 11.9592 12.1304 24.2703 12.3111 101.49 0.6889

11.9592 14.3957 26.5306 14.5714 101.22 0.7734

'Mean of six observations. RSD: relative standard deviation.

Table 3: Repeatability data for proposed method.

Serial number Concentration (^g/mL) Absorbance of PARA at 305.5 nm Absorbance ofAMB at 321 nm Absorbance of LEVO at 244 nm Absorbance of PHEN at 280 nm

1 10ppm 0.0199 0.0027 0.0121 0.0054

2 10ppm 0.0200 0.0028 0.0120 0.0053

3 10ppm 0.0203 0.0027 0.0119 0.0052

4 10ppm 0.0200 0.0027 0.0120 0.0052

5 10ppm 0.0201 0.0028 0.0120 0.0051

6 10ppm 0.0200 0.0027 0.0121 0.0053

Mean 0.0201 0.0027 0.0120 0.0052

SD 0.00014 0.000052 0.000075 0.0001

% RSD 0.6874 1.8892 0.6264 1.9977

SD: standard deviation; RSD: relative standard deviation.

Table 4: Intraday and interday precision data of PARA, AMB, LEVO and PHEN.

Drug Amount labeled (mg/tab) Percentage obtained (« = 6) SD % , RSD

Intraday Interday Intraday Interday Intraday Interday

500 99.47 99.60

PARA 500 98.61 99.48 0.4936 0.0723 0.4977 0.0726

500 99.46 99.61

Mean 99.18 99.56

60 98.56 97.85

AMB 60 100.44 100.83 0.9408 1.6197 0.9453 1.6244

60 99.57 100.44

Mean 99.52 99.72

2.5 99.88 100.01

LEVO 2.5 100.01 99.88 0.0750 0.0751 0.0752 0.0750

2.5 99.88 100.01

Mean 99.92 99.96

5 98.21 98.34

PHEN 5 98.34 98.22 0.0750 0.0752 0.0765 0.0763

5 98.21 98.34

Mean 98.25 98.29

SD: standard deviation; RSD: relative standard deviation; CI: confidence interval; SE: standard error.

Table 5: Assay results of marketed formulation.

Parameters PARA AMB LEVO PHEN

Actual concentration (^g/mL) 60 12 12 12

Percentage purity 99.62 101.02 100.98 99.66

% RSD 0.1661 1.9231 1.6141 1.1750

method is shown in Table 5. The percentage purity was 99.62% ± 0.1655 for PARA, 101.02% ± 1.9427 for AMB, 100.98% ± 1.6300 for LEVO, and 99.66% ± 1.1711 for PHEN.

5. Conclusion

In this proposed method, the linearity was observed in the concentration ranges of 20-140 ^g/mL, 10-70 ^g/mL, 1070 ^g/mL, and 10-70 ^g/mL while coefficients of correlation were r2 = 0.9992, r2 = 0.9990, r2 = 0.9990, and r2 = 0.9995 for PARA, AMB, LEVO, and PHEN at 305.5 nm, 321 nm, 244 nm, and 280 nm, respectively The result of the analysis of combined mixture by the proposed method was found to be highly reproducible and reliable. The additive present in the combined mixture of the assayed samples did not interfere with determination of PARA, AMB, LEVO, and PHEN. So, the developed first derivative UV spectrophotometric method is simple, precise, accurate, and reproducible and can be effectively used for the simultaneous determination of PARA, AMB, LEVO, and PHEN in combined tablet dosage form.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors are thankful to Madras Pharmaceuticals Chen-nai, Tamil Nadu, India, Medopharm Pvt., Ltd., Chennai, Tamil Nadu, India, and APEX Pharmaceuticals Pvt., Ltd., Chennai, Tamil Nadu, India for providing standard raw materials of PARA, AMB, LEVO, and PHEN. The authors are also thankful to Dr. T. Vetrichelvan, Principal, Adhiparasak-thi College of Pharmacy, Melmaruvathur, for providing the necessary facilities to carry out the research work.

References

[1] Indian Pharmacopoeia, vol. 3, Pharmacopoeia Commision, Ministry of Health & Family Welfare, Ghaziabad, India, 6th edition, 2010.

[2] British Pharmacopoeia, vol. 3, British pharmacopoeia Commision Office, London, UK, 2010.

[3] B. G. Ragul and M. P. Arun, "Spectrophotometric method for simultaneous estimation of ambroxol hydrochloride, levo-cetrizine dihydrochloride and phenylephrine hydrochloride in tablet dosage form," International Research Journal ofPharmacy, vol. 4, pp. 197-200, 2013.

[4] I. Ponnilavarasan, C. S. Narendra, and P. Asha, "Simultaneous estimation of ambroxol hydrochloride and loratadine in tablet dosage form by using UV spectrophotometric method," International Journal ofPharma and Bio Sciences, vol. 2, no. 2, pp. 338-344, 2011.

[5] K. Parmar, S. Baldania, D. Shah, U. Chhalotiya, and N. Par-mar, "Development and validation of first-order derivative spectrophotometry for simultaneous determination of levocetirizine dihydrochloride and phenylephrine hydrochloride in pharmaceutical dosage form," International Journals of Spectroscopy, vol. 3, pp. 1-6, 2013.

[6] S. Prabu, A. Shirwaikar, A. Shirwaikar, C. Kumar, and G. Kumar, "Simultaneous UV spectrophotometric estimation of ambroxol hydrochloride and levocetirizine dihydrochloride," Indian Journal ofPharmaceutical Sciences, vol. 70, no. 2, pp. 236238, 2008.

[7] L. K. Soni, T. Narsinghani, and C. Saxena, "DUV spectrophotometric estimation of ebastine and phenylephrine hydrochloride in tablet dosage form using absorption ratio method," Der Pharmacia Sinica, vol. 2, pp. 11-16, 2011.

[8] M. Patel, B. Patel, and S. Parmar, "Simultaneous estimation of ibuprofen and phenylephrine hydrochloride in bulk and combined dosage form by first derivative UV spectrophotometry method," Creative Commons Attribution License, vol. 2, pp. 198201, 2013.

[9] A. Manikantakumar, A. Swathi, D. Supriya, L. N. Prasad, V. Prakash, and V. Diwan, "Development and validation of UV spectrophotometric method for simultaneous estimation of ibuprofen, paracetamol and caffeine in pharmaceutical dosage form," American Journal of Pharmatech Research, vol. 2, pp. 540-547, 2012.

[10] R. Sawant, R. Joshi, M. Sawant, P. Lanke, and L. Bhangale, "Mathematical and multiwavelength spectrophotometric methods for simultaneous estimation of paracetamol, phenylephrine hydrochloride, chlorpheniramine maleate and caffein," International Journal ofPharmaceutical Frontier Research, vol. 1, pp. 3138, 2011.

[11] P. Y. Pawar, H. Sandip, S. Megha, and A. Arti, "Spectrophotometric estimation and validation of paracetamol and domperi-done by different method from pure and tablet dosage form," International Journal of Drug Research and Technology, vol. 3, pp. 37-44, 2013.

[12] G. Nagamalleswari, A. Prabahar, and N. Ramarao, "Simultaneous quantitative estimation of levocetirizine and phenylephrine by different analytical methods," International Journal ofPharmaceutical Research, vol. 5, pp. 214-222, 2013.

[13] P. Malakar, A. R. Deb, S. Adhikary, S. Ahmed, and R. Mal-oth, "Simultaneous estimation of phenylephrine hydrochloride, paracetamol, caffeine and cetirizine dihydrochloride from tablet dosage form using RP-HPLC," International Journal of Biological & Pharmaceutical Research, vol. 4, pp. 368-376,2013.

[14] P. Mahesh, K. Swapnalee, M. Aruna, B. Anilchandra, and S. Prashanti, "Analytical method development and validation of acetaminophen, caffeine, phenylephrine hydrochloride and dextromethorphan hydrobromide in tablet dosage form by RP-HPLC," Inventi Journal ofPharmaceutical Science Invention, vol. 2, pp. 9-15, 2013.

[15] S. R. Pattan, S. G. Jamdar, R. K. Godge et al., "RP- HPLC method for simultaneous estimation of paracetamol and etoricoxib from bulk and tablets," Journal of Chemical and Pharmaceutical Research, vol. 1, pp. 329-335, 2009.

[16] P. M. Sanchaniya, F. A. Mehta, and N. B. Uchadadiya, "Development and validation of an RP-HPLC method for estimation of chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride in combined pharmaceutical dosage form," Chromatographic International Research, vol. 2013, Article ID 424865, 6 pages, 2013.

[17] M. P. Arun and B. G. Rahul, "Development and validation of RP-HPLC method for simultaneous determination of ambroxol hydrochloride, levocetirizine dihydrochloride and phenylephrine hydrochloride in combined dosage form," Inventi Rapid: Pharmaceutical Analysis & Quality Assurance, Article ID Inventi:ppaqa/864/13, 2013.

[18] S. Gopalakrishnan, T. A. Chitra, A. Aruna, and A. Chenthilnathan, "Development of RP-HPLC method for the simultaneous estimation of ambroxol hydrochloride, cetirizine hydrochloride and antimicrobial preservatives in combined dosage form," Der Pharma Chemica, vol. 4, pp. 1003-1015, 2012.

[19] G. Bazylak and L. J. Nagels, "Simultaneous high-throughput determination of clenbuterol, ambroxol and bromhexine in pharmaceutical formulations by HPLC with potentiometric detection," Journal of Pharmaceutical and Biomedical Analysis, vol. 32, no. 4-5, pp. 887-903, 2003.

[20] J. Goswami, J. Kakadiya, and N. Shah, "RP-HPLC method development and validation for simultaneous estimation of ambroxol hydrochloride and cefpodoxime proxetile in pharmaceutical dosage form," American Journal of Pharmatech Research, vol. 2, pp. 1043-1052, 2012.

[21] P. Chandra and A. S. Rathore, "Application of HPLC for the simultaneous determination of aceclofenac, paracetamol and tramadol hydrochloride in pharmaceutical dosage form," Scientia Pharmaceutica, vol. 8, pp. 337-351, 2012.

[22] R. Sawant, R. Joshi, P. Lanke, and L. Bhangale, "Simultaneous estimation & validation of paracetamol, phenyle-phrine hydrochloride and chlorpheniramine maleate in tablets by spectrophotometric method," Journal of Pharmaceutical Research and Health Care, vol. 3, no. 2, pp. 23-28, 2011.

[23] R. K. Trivedi, M. C. Patel, and S. B. Jadhav, "A rapid, stability indicating RP-UPLC method for simultaneous determination of ambroxol hydrochloride, cetirizine hydrochloride and antimicrobial preservatives in liquid pharmaceutical formulation," Scientia Pharmaceutica, vol. 79, no. 3, pp. 525-543, 2011.

[24] J. M. Reddy, M. R. Jeyaprakash, K. Madhuri, S. N. Meyyanathan, and K. Elango, "A sensitive RP-HPLC method for simultaneous estimation of diethylcarbamazine and levocetirizine in tablet formulation," Indian Journal ofPharmaceutical Sciences, vol. 73, no. 3, pp. 320-323, 2011.

[25] V. Maslarska and J. Tencheva, "Simultaneous determination and validation of paracetamol and codeine phosphate in pharmaceutical preparation by RP-HPLC," International Journal of Pharmaceutical Science, vol. 5, pp. 417-419, 2013.

[26] M. Maithani, R. Raturi, V. Gautam et al., "Development and validation of a RP-HPLC method for the determination of chlorpheniramine maleate and phenylephrine in pharmaceutical dosage form," Pharmacie Globale: International Journal of Comprehensive Pharmacy, vol. 5, pp. 8146-8157, 2010.

[27] G. Nagamalleswari, "Development and validation of a chromatographic method for simultaneous estimation of levo-cetrizine and phenylephrine in pharmaceutical dosage form," International Journal of Advances in Pharmaceutical Research, vol. 4, pp. 1921-1926, 2013.

[28] D. R. Urwashi and S. P. Wate, "RP-HPLC method development and validation for simultaneous estimation of levocetirizne dihydrochloride and phenylephrine hydrochloride in their tablet dosage form," Asian Journals of Research and Chemistry, vol. 6, pp. 1-3, 2013.

[29] R. Kimbahune, K. Sunil, P. Kabra, K. Delvadiya, and S. Surani, "Spectrophotometric simultaneous analysis of Ambroxol

hydrochloride, Guaifenesin and Terbutaline sulphate in liquid dosage form (syrup)," International Journal of Pharmaceutical Sciences Review and Research, vol. 8, no. 2, pp. 24-28, 2011.

[30] R. S. Wagh, R. A. Hajare, A. Tated, and A. V. Chandewar, "Absorption correction method and simultaneous equation method for the simultaneous estimation of ebastine and phenylephrine hydrochloride in bulk and in combined tablet dosage form," International Journal of Research in Pharmacy and Chemistry, vol. 1, pp. 812-818, 2011.

[31] M. S. Arayne, N. Sultana, A. Z. Mirza, and F. A. Siddiqui, "Simultaneous determination of gliquidone, fexofenadine, buclizine, and levocetirizine in dosage formulation and human serum by RP-HPLC," Journal of Chromatographic Science, vol. 48, no. 5, pp. 382-385, 2010.

[32] K. A. Shaikh and A. T. Patil, "A stability-indicating LC method for the simultaneous determination of levocetirizine dihydrochloride and pseudoephedrine sulfate in Tablet dosage forms," International Journal ofChemTech Research, vol. 2, no. 1, pp. 454-461, 2010.

[33] K. A. Shaikh, S. D. Patil, and A. B. Devkhile, "Development and validation of a reversed-phase HPLC method for simultaneous estimation of ambroxol hydrochloride and azithromycin in tablet dosage form," Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 5, pp. 1481-1484, 2008.

[34] A. L. Suryan, V. K. Bhusari, K. S. Rasal, and S. R. Dhaneshwar, "Simultaneous quantitation and validation of paracetamol, phenylpropanolamine hydrochloride and cetirizine hydrochloride by RP-HPLC in bulk drug and formulation," International Journal of Pharmaceutical Sciences and Drug Research, vol. 3, pp. 303-308, 2011.

[35] R. Suresh, R. Manavalan, and K. Valliappan, "HPLC method for the simultaneous determination of levocetirizine, ambroxol and montelukast in human plasma employing response surface methodology," International Journal of Drug Development & Research, vol. 4, pp. 173-185, 2012.

[36] R. S. Wagh, R. A. Hajare, A. G. Tated, P. A. Gadbali, F. A. Khan, and S. D. Kayal, "Method development and validation for simultaneous determination of ebastine and phenylephrine hydrochloride in tablet formulation by RP-HPLC," International Journal of Pharmaceutical Research and Development, vol. 3, pp. 214-220, 2011.

[37] S. A. Rathore, L. Sathiyanarayanan, and K. R. Mahadik, "Development of validated HPLC and HPTLC methods for simultaneous determination of levocetirizine dihydrochloride and montelukast sodium in bulk drug and pharmaceutical dosage form," Journal of Pharmaceutica Analytica Acta, vol. 1, pp. 1-6, 2010.

[38] R. C. Anuruddha, T. Vishakha, L. D. Deepali, H. S. Mansi, S. K. Bhanudas, and S. Shailesh, "Development and validation of HPTLC method for simultaneous estimation of paracetamol, ibuprofen and caffeine in bulk and pharmaceutical dosage form," Reseacch Journal of Pharmacy and Technology, vol. 5, pp. 1218-1222, 2012.

[39] T. Raja and A. L. Rao, "Development and validation of HPTLC method for the simultaneous estimation of gemifloxacin mesylate and ambroxol hydrochloride in bulk and tablet dosage form," Analytical Chemistry Letters, vol. 2, pp. 152-158, 2013.

[40] F. Su, F. Wang, W. Gao, and H. Li, "Determination of ambroxol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI)," Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 853, no. 1-2, pp. 364-368,2007.

[41] H. Kim, J.-Y. Yoo, S. B. Han, H. J. Lee, and K. R. Lee, "Determination of ambroxol in human plasma using LC-MS/MS," Journal of Pharmaceutical and Biomedical Analysis, vol. 32, no. 2, pp. 209-216, 2003.

[42] ICH Tripartite Guidelines, Q2R1 Validation of Analytical Procedures: Text and Methodology, ICH, Geneva, Switzerland, 2005.

[43] ICH Tripartite Guidelines, Q2B Validation of Analytical Procedures: Text and Methodology, ICH, Geneva, Switzerland, 1996.

Copyright of ISRN Otolaryngology is the property of Hindawi Publishing Corporation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.